A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents - Full Text View

Sponsor:	King Pharmaceuticals
Information provided by:	King Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00389519

Purpose

The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.

Condition	Intervention	Phase
Hypertension	Drug: ramipril Drug: placebo	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm Study Assessing the Efficacy, Safety, and Dose-Response of Ramipril for the Treatment of Hypertension in Children and Adolescents

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure Potassium

Drug Information available for: Ramipril

U.S. FDA Resources

Further study details as provided by King Pharmaceuticals:

Primary Outcome Measures:

Change From Baseline to 4 Weeks in Trough Sitting Systolic Blood Pressure [ Time Frame: Baseline to 4 weeks ] [ Designated as safety issue: No ]
Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo

Secondary Outcome Measures:

Change From Baseline to 4 Weeks in Trough Sitting Diastolic Blood Pressure [ Time Frame: Baseline to 4 weeks ] [ Designated as safety issue: No ]
Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo
Change From Baseline to 4 Weeks in Serum Creatinine [ Time Frame: Baseline up to 4 weeks ] [ Designated as safety issue: Yes ]
Value at end of treatment (up to 4 weeks) minus value at baseline
Change From Baseline to 4 Weeks in Serum Potassium [ Time Frame: Baseline up to 4 weeks ] [ Designated as safety issue: Yes ]
Value at end of treatment (up to 4 weeks) minus value at baseline
Change From Baseline to 4 Weeks in Schwartz Formula Glomerular Filtration Rate (GFR) [ Time Frame: Baseline up to 4 weeks ] [ Designated as safety issue: Yes ]
Value at end of treatment (up to 4 weeks) minus value at baseline; GFR is a measure of kidney function.

Enrollment:	422
Study Start Date:	October 2006
Study Completion Date:	November 2007
Primary Completion Date:	November 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Placebo once per day	Drug: placebo once a day oral placebo capsule for 4 weeks
Experimental: ramipril low dose 0.3125, 0.625, or 1.25 mg once a day, based on subject weight	Drug: ramipril once a day oral ramipril capsules given for 4 weeks Other Name: Altace
Experimental: ramipril mid dose 1.25, 2.5, or 5 mg once a day, based on subject weight	Drug: ramipril once a day oral ramipril capsules given for 4 weeks Other Name: Altace
Experimental: ramipril high dose 5, 10, or 20 mg once a day, based on subject weight	Drug: ramipril once a day oral ramipril capsules given for 4 weeks Other Name: Altace

Detailed Description:

Information is needed on the treatment of hypertension in children and adolescents with antihypertensive drugs like ramipril. The study will assess the safety and blood pressure effects of several doses of the antihypertensive drug ramipril in children and adolescents age 6-16 years. Approximately 450 children will be given placebo, or 1 of the 3 doses of ramipril. The treatment assigned will be done by chance, like flipping a coin. Approximately 120 study centers throughout the world will participate in the trial.

Each child will complete a 1- to 4-week Screening Period where they will stop taking their current blood pressure lowering drug(s), a 4-week Treatment Period where they will receive placebo or one of the ramipril doses, and a Follow-up visit 1 week after completion of the Treatment Period. Children diagnosed with hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (U.S. report), will be included in the study if their blood pressure meets certain values.

Each child will complete a minimum of 6 and up to 9 clinic visits over the course of the study during which procedures and assessments of blood pressure and safety will be performed. In addition, a child's parents/guardians will be instructed to measure their child's blood pressure at home between clinic visits.

A planned interim analysis was performed after approximately 240 subjects completed the trial. The study was stopped, as permitted by protocol, after the analysis.

Eligibility

Ages Eligible for Study:	6 Years to 16 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Previous, documented diagnosis of hypertension, or newly diagnosed hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (United States). SiSBP greater than or equal to the 95th percentile for age, gender, and height.
The subject can be safely withdrawn from antihypertensive medications during the screening period, and if given placebo during the treatment period in the judgment of the Investigator.
The subject is male or female age 6 to 16 years (inclusive), and weighs greater than or equal to 20 kg.
Female subjects greater than or equal to 12 years of age, or who have had greater than or equal to 1 menstruation must: (a) have a negative serum pregnancy test at screening (i.e., subject is not pregnant), (b) not be lactating, and (c) use an acceptable method of contraception.
Parents/guardians are able to demonstrate their ability to (a) use a home blood pressure monitor supplied for the study to monitor their child's blood pressure, and (2) mix and administer a liquid dose of study drug if needed.

Exclusion Criteria:

Bilateral renal artery stenosis.
Uncorrected coarctation of the aorta or corrected coarctation with a right arm/right leg blood pressure gradient greater than 10 mmHg.
Severe hypertension.
Renal transplantation or other previous solid organ transplantation less than 6 months prior to entering the study.
Subjects with nephrotic syndrome not on stable maintenance therapy of prednisone or cyclosporine.
A history of cardiomyopathy, clinically significant structural heart disease, or atrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrial fibrillation, clinically significant bradycardia or an accessory bypass tract, or clinical symptoms of congestive heart failure.
Clinically significant hematologic, hepatobiliary, or renal disease including a Schwartz formula GFR less than 40 mL/min/1.73 m2, and/or serum potassium (K+) greater than 5.5 mEq/L.
History of pancreatitis (active or inactive).
Known sensitivity to angiotensin converting enzyme inhibitors or a history of angioneurotic edema.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00389519

Show 101 Study Locations

Sponsors and Collaborators

King Pharmaceuticals

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00389519 History of Changes
Other Study ID Numbers:	K726-06-4003
Study First Received:	October 17, 2006
Results First Received:	January 21, 2010
Last Updated:	April 29, 2010
Health Authority:	United States: Food and Drug Administration; Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica; Brazil: Ministry of Health; Canada: Health Canada; Chile: Instituto de Salud Publica de Chile; Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos; India: Ministry of Health; Poland: Ministry of Health; South Africa: Medicines Control Council; Turkey: Ministry of Health; Ukraine: Ministry of Health

Keywords provided by King Pharmaceuticals:

Hypertension/*etiology
Blood Pressure
Pediatric
Adolescent
Child

Additional relevant MeSH terms:

Hypertension
Vascular Diseases
Cardiovascular Diseases
Ramipril
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors

Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2012